Modernizing and Ensuring PBM Accountability Act

Issues related to pharmacy benefit management, including in H.R. 5378 (Lower Costs, More Transparency Act), S.2973 (Modernizing and Ensuring PBM Accountability Act), S.1339 (Pharmacy Benefit Manager Reform Act), and H.R.10545 (American Relief Act, 2025).

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2973 - Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430 - Mental Health, Lower-Cost Drug and Extenders Package Correspondence with U.S. Senate and U.S. House of Representatives in support of the legislation to help ensure that patients realize cost savings on their prescription drugs; research relating thereto.

Client expense: $10,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to pharmacy benefit management, including in H.R. 5378 (Lower Costs, More Transparency Act), S.2973 (Modernizing and Ensuring PBM Accountability Act), S.1339 (Pharmacy Benefit Manager Reform Act), and H.R.10545 (American Relief Act, 2025).

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare Advantage, H.R.1 One Big Beautiful Bill Act, Pharmacy Benefit Manager Issues, Issues relating to Health Insurance, S.2973 - Modernizing and Ensuring PBM Accountability Act, S.1339 Pharmacy Benefit Manager Reform Act, General Business Issues, S.1105 - No UPCODE Act

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmacy Benefit Manager Issues, H.R.5378 - Lower Costs, More Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.1- One Big Beautiful Bill Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 705: Innovation in Pediatric Drugs Act of 2025 S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 H.R. 946: Orphan Cures Act H.R. 1262: Give Kids a Chance Act of 2025 H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues Clinical trial policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Provisions related to the pharmaceutical industry. Drug cost and pricing policy issues Drug importation policy issues Accelerated approval policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program Issues related to the 340B Program. Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Patent use codes policy issue Pharmacy Benefit Manager reform and policy issues Rebate policy issues S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA) S. 882, Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform. The Orphans Cures Act" User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Vaccine provisions of the Inflation Reduction Act

Client expense: $800,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

S. 705: Innovation in Pediatric Drugs Act of 2025 S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 H.R. 946: Orphan Cures Act H.R. 1262: Give Kids a Chance Act of 2025 H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues Clinical trial policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Provisions related to the pharmaceutical industry. Drug cost and pricing policy issues Drug importation policy issues Accelerated approval policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program Issues related to the 340B Program. Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Patent use codes policy issue Pharmacy Benefit Manager reform and policy issues Rebate policy issues S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA) S. 882, Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform. The Orphans Cures Act" User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Vaccine provisions of the Inflation Reduction Act

Client expense: $800,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Issues related to pharmacy benefit management, including in H.R. 5378 (Lower Costs, More Transparency Act), S.2973 (Modernizing and Ensuring PBM Accountability Act), S.1339 (Pharmacy Benefit Manager Reform Act), and H.R.10545 (American Relief Act, 2025).

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act

Client expense: $870,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmacy Benefit Manager Issues, H.R.5378 - Lower Costs, More Transparency Act, H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025, S.150 - Affordable Prescriptions for Patients Act of 2023, S.1339 - Pharmacy Benefit manager Reform Act, S.2973 - Modernizing and Ensuring PBM Accountability Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmacy Benefit Manager Issues, Issues relating to Health Insurance, Medicare Advantage, S.2973 - Modernizing and Ensuring PBM Accountability Act, S.1339 Pharmacy Benefit Manager Reform Act

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare Part B Issues; Drug pricing and access, including Inflation Reduction Act; Drug shortage issues; Medicare physician reimbursement issues; HR 405-EMSSA; HR 5378-Lower Costs, More Transparency Act; S.2973-Modernizing and Ensuring PBM Accountability Act; HR 5526-Seniors'Access to Critical Medications Act of 2023; S.2764 and HR 5391, the Protecting Patient Access to Cancer and Complex Therapies Act, Seniors Access to Critical Medications Act (H.R. 5526).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE

340B, Medicare Part D, Medicare Part B Issues, Importation of Drugs, Drug Pricing, Coronavirus Issues, Inflation Reduction Act, TRIPs Waiver, insurance coverage issues and Inflation Reduction Act implementation, March-in rights - Biden Administration announcement, HR 5378-LowerCosts, More Transparency Act; S.2973-Modernizing and Ensuring PBM Accountability Act, HR 7174, The EPIC Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The 340B Drug Pricing Program; H.R. 2534, The Protect 340B Act; FY24 and FY25 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bills. HR 3290,to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.3561 - PATIENT Act of 2023, The Stop Drug Shortages Act (Draft legislation- House), H.R. 5378: Lower Costs, More Transparency Act, S. 1182: 340B Reporting and Accountability Act; S.1133: 340B Accountability Act of 2023,S.1038: Drug Price Transparency in Medicaid Act of 2023,H.R.1613: Drug Price Transparency in Medicaid Act of 2023,H.R.198: Drug Pricing Transparency and Accountability Act; S. 2973: Modernizing and Ensuring PBM Accountability Act, Draft Senate legislation the SUSTAIN 340B Act, HR 7635 and S. 5021, the 340B PATIENTS Act.H.R. 8574, 340B ACCESS Act: H.R.8144 - Rural 340B Access Act of 2024

Client expense: $345,454 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE

Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act

Client expense: $1,600,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office

PBM Transparency and Reform: S1375/HH830 - Help Ensure Lower Patient (HELP) Copays Act S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act S2973 - Modernizing and Ensuring PBM Accountability Act S3430 - Better Mental Health Care, Lower Cost Drugs, and Extenders Act HR5378 - Lower Costs More Transparency Act Inflation Reduction Act /Medicare Price Setting 340B Reform Cell and Gene Therapy Access Model HR1458 - Access to Prescription Digital Therapeutics Act of 2023

Client expense: $3,740,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act

Client expense: $2,390,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office

H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027.";

Client expense: $340,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office

The 340B Drug Pricing Program; H.R. 2534, The Protect 340B Act; FY24 and FY25 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bills. HR 3290,to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.3561 - PATIENT Act of 2023, The Stop Drug Shortages Act (Draft legislation- House), H.R. 5378: Lower Costs, More Transparency Act, S. 1182: 340B Reporting and Accountability Act; S.1133: 340B Accountability Act of 2023,S.1038: Drug Price Transparency in Medicaid Act of 2023,H.R.1613: Drug Price Transparency in Medicaid Act of 2023,H.R.198: Drug Pricing Transparency and Accountability Act; S. 2973: Modernizing and Ensuring PBM Accountability Act, Draft Senate legislation the SUSTAIN 340B Act, HR 7635 and S. 5021, the 340B PATIENTS Act.H.R. 8574, 340B ACCESS Act: H.R.8144 - Rural 340B Access Act of 2024

Client expense: $260,046 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE

Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act

Client expense: $2,830,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office

Pharmacy Benefit Manager Transparency Act S.127; PBM reform bills; H.R.3561 The PATIENT Act; S.2973 MEPA;

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1692 / S 8, the Health Care Affordability Act; HR 2630 / S 652, the Safe Step Act; HR 3433 / S 2897, the Give Kids a Chance Act; HR 3503 / S 1701, The NIH Clinical Trial Diversity Act; HR 3991 / S 1624, the Gabriella Miller Kids First Act; HR 4363 / S 2213, Comprehensive Cancer Survivorship Act; HR 6003 / S 3103, the Medical Debt Relief Act; HR 6301 / S. 2039, The Cancer Drug Parity Act; HR 7383 / S 1214, the RARE Act; HR 8311 / S 4289, Medical Debt Cancellation Act; HR 824, the Telehealth Benefit Expansion for Workers Act; HR 1773, the Consumer Protection for Medical Debt Collections Act; HR 2813, Self-Insurance Protection Act; HR 2868, the Association Health Plans; HR 2880, the Protecting Patients Against PBM Abuses Act; HR 3799, CHOICE Arrangement Act; HR 3800, the Chronic Disease Flexible Coverage Act; HR 5609, the Advancing Health Savings Act; HR 5688, the Bipartisan HSA Improvement Act; HR 5687, the HSA Modernization Act; HR 6664, the Innovation in Pediatric Drugs Act; HR 6963, the Pediatric Cancer Drug Supply Chain Act; HR 7384, the Creating Hope Reauthorization Act; HR 8261, Preserving Telehealth, Hospital, and Ambulance Access Act; HR 8412, the Clinical Trial Modernization Act; HR 8574, the 340B ACCESS Act; HR 9129, Patient Debt Relief Act; S 113, the Prescription Pricing for the People Act; S 127, the Pharmacy Benefit Manager Transparency Act; S 1339, the Pharmacy Benefit Manager Reform Act; S 1542, the DRUG Act; S 1967 the Patients Before Middlemen Act; S 2243, the Palliative Care and Hospice Education and Training Act; S 2483, the Strengthening Consumer Protections and Medical Debt Transparency Act; S 2973, the Modernizing and Ensuring PBM Accountability Act; S 3167, Multiple Employer Welfare Arrangement (MEWA) Act; HR 9774 / S 5194, the Health Care Affordability Act; Legislation to protect insurance purchasers interacting with insurance brokers; Implementation of the No Surprises Act; Federal rulemaking related to Short-term Limited Duration Insurance (STLDI) plans; Efforts to extend and make permanent the current enhanced Advance Premium Tax Credits; Insurance appeals and denials; Federal rulemaking related to Association Health Plans; Consumer protections related to consumers who will lose insurance due to the end of certain federal Medicaid maintenance-of-effort requirements; FDA draft guidance related to dose optimization studies in clinical trials

Client expense: $180,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Biosimilar Red Tape Elimination Act (S. 2305) Drug Patent Reform Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing, Rebates, Delinking Protecting Patients Against PBM Abuses Act (H.R. 2880) Drug Act (H.R. 6283) Robinson-Patman Act Reform Modernizing and Ensuring PBM Accountability (MEPA) Act (S.2973) Pharmacy Benefit Manager Transparency Act (S. 127) Pharmacy Benefit Manager Reform Act (S. 1339) Patients Before Middlemen Act (S.1967) Prescription Pricing for the People Act (S.113) Drug-Price Transparency for Consumers Act (S. 1250) Lower Cost, More Transparency Act (H.R. 5378) Continuing Resolution (H.R. 10545)

Client expense: $1,210,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE

H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023 - Rep. Carter, Earl - spread-pricing by PBMs for Medicaid H.R. 2880 - Protecting Patients Against PBM Abuses Act - Rep. Carter, Earl - PBM transparency H.R. 4818 - Treat and Reduce Obesity Act - Rep. Wenstrup, Brad - weight loss coverage H.R. 5372 - Expanding Seniors Access to Lower Cost Medicines Act of 2023 - Rep. Joyce, John - generic drugs, biosimilars cost H.R. 5378 - Lower Costs, More Transparency Act - Rep. McMorris Rodgers, Cathy - PBM transparency H.R. 5385 - Medicare PBM Accountability Act - Rep. Landsman, Greg McMorris - PBM transparency H.R. 6283 - DRUG Act - Rep. Miller-Meeks, Mariannette - PBM contracts H.R. 10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 - Rep. Cole, Tom - PBM regulation S. 79 - Interagency Patent Coordination and Improvement Act of 2023 - Sen. Durbin, Richard - prescription drug patenting S. 113 - Prescription Pricing for the People Act of 2023 - Sen. Grassley, Chuck - PBM transparency S. 127 - Pharmacy Benefit Manager Transparency Act of 2023 - Sen. Cantwell, Maria - PBM transparency S. 142 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - pharmacy and biosimilar prescription drugs S. 148 - Stop STALLING Act - Sen. Klobuchar, Amy - pharmacy market approval processes S. 150 - Affordable Prescriptions for Patients Act of 2023 - Sen. Cornyn, John - pharmacy and prescription drug prices, prevent patent thickets S. 574 - Increasing Prescription Drug Competition Act - Sen. Hassan, Maggie - closure of pharmaceutical patent loophole S. 652 - Safe Step Act - Sen. Murkowski, Lisa - medication step therapy protocol S. 954 - Affordable Insulin Now Act of 2023 - Sen. Warnock, Raphael - insulin pricing and cost sharing S. 1269 - INSULIN Act of 2023 - Sen. Shaheen, Jeanne - insulin pricing S. 1339 - Pharmacy Benefit Manager Reform Act - Sen. Sanders, Bernie - PBM transparency S. 1542 - DRUG Act - Sen. Marshall, Roger - PBM regulation S. 2973 - Modernizing and Ensuring PBM Accountability Act - Sen. Wyden, Ron - Plan implementation S. 3934 - Increasing Access to Biosimilars Act of 2023- Sen. Cornyn, John - Medicare drug access Issues related to the implementation of Inflation Reduction Act - Medicare negotiation; coverage of weight loss drugs; high priced drugs; patent reforms; Pharmacy Benefit Managers; and copay coupons.

Client expense: $2,610,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmacy Benefit Manager (PBM) Reform Pharmacy Direct and Indirect Remuneration (DIR) Reform Pharmacy Reimbursement and Scope of Practice Modernizing and Ensuring PBM Accountability (MEPA) Act, S. 2973 Lower Costs, More Transparency Act, H.R. 5378 Drug Price Transparency in Medicaid Act, H.R.1613/S. 1038 Equitable Community Access to Pharmacist Services Act, H.R. 1770/S. 2477 S. 3430, Better Mental Health Care, Lower-Cost Drugs, and Extenders Act Pharmacy reimbursement and DIR fees under the Inflation Reduction Act FY 2025 continuing resolution: H.R. 10445, H.R. 10515, H.R. 10545 Seniors Access to Critical Medications Act of 2024, H.R. 5526/S. 3458

Client expense: $140,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Education about the 340(b) program. H.R.830 - HELP Copays Act. H.R.5378 - Lower Costs, More Transparency Act. S.2973 - Modernizing and Ensuring PBM Accountability Act. H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act. H.R.2880 - Protecting Patients Against PBM Abuses Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES

H.R. 7142/S. 3832, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act; H.R. 5378, The Lower Costs, More Transparency Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues pertaining to CHANGE cyber attack; Monitoring of Medicare Advantage, particularly as it relates to changes in coding intensity, benchmarks, and health risk assessments; Telehealth extension; Issues related to Medicare provider directories; Issues related to Medicare Advantage marketing practices, prior authorization; S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act; H.R. 5378, Lower Costs, More Transparency Act; Issues related to 2025 Medicare Part D Bid Information and Announces Premium Stabilization Demonstration; Calendar Year (CY) 2025 Rate Announcement for the Medicare Advantage (MA) and Medicare Part D Prescription Drug (Part D) Programs (Rate Notice); Issues related to the use of AI and it's correlation to prior authorization and utilization management policies

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Preventing Maternal Deaths Reauthorization Act of 2023 (H.R. 3838/S. 2415) SUSTAIN 340B Act (not introduced) Accelerating Kids Access to Care Act (H.R. 4758) SHINE for Autumn Act of 2023 (S. 2647) Modernizing and Ensuring PBM Accountability Act (S.2973) Maternal and Infant Syphilis Prevention Act (H.R. 8839) Health Equity and Accountability Act of 2024 (S. 4773/H.R. 9161) Stabilize Medicaid and CHIP Coverage Act 0-(S. 3138/H.R. 5434) Jeanette Acosta Invest in Women's Health Act (H.R. 10287/S. 5428) Nomination of Mehmet Oz for Administrator of Centers for Medicare and Medicaid Services

Client expense: $497,365 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 456: Fairness in Orphan Drug Exclusivity Act H.R. 766: Dr. Michael C. Burgess Preventive Health Savings Act H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1613: Drug Price Transparency in Medicaid Act of 2023 H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program H.R. 2679: Pharmacy Benefits Manager Accountability Act H.R. 2707: MADE in America Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3433: Give Kids a Chance Act of 2024 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3839: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act H.R. 4818: Treat and Reduce Obesity Act of 2023 H.R. 4895: Lowering Drug Costs for American Families Act - Provisions related to drug pricing H.R. 4988: Modern Authentication of Pharmaceuticals Act of 2023 H.R. 5376: Share the Savings with Seniors Act  H.R. 5378: Lower Costs, More Transparency Act H.R. 5391: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 5539: ORPHAN Cures Act H.R. 6283: Delinking Revenue from Unfair Gouging or DRUG Act H.R. 6664: Innovation in Pediatric Drugs Act of 2023 H.R. 7024 Tax Relief for American Families and Workers Act of 2024 H.R. 7174: Ensuring Pathways to Innovative Cures (EPIC) Act: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7248: FDA Modernization Act 3.0 H.R. 7623: Telehealth Modernization Act of 2024 H.R. 7635: The 340B PATIENTS Act of 2024 H.R. 8574: 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act H.R. 9096: Pharmacists Fight Back Act S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1130: Health Care PRICE Transparency Act S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 1589: Safeguarding Patients and Taxpayers Act S. 1967: PBM Act S. 2305: Biosimilar Red Tape Elimination Act S. 2333: Pandemic and All-Hazards Preparedness and Response Act S. 2474: Share the Savings with Seniors Act S. 2477: Equitable Community Access to Pharmacist Services Act S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA) S. 3393: SUPPORT for Patients and Communities Reauthorization Act S. 3430: Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S. 5021: 340B PATIENTS Act of 2024 S. 5040: Protecting Patients from Deceptive Drugs Online Act S. 5459: Biosimilars Access and Affordability Act BioCompete Act (draft) Executive Order of February 28, 2024, Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) User fee policy issues Inflation Reduction Act of 2022 (P.L. 117-169) IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues Clinical trial diversity policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues Vaccine provisions of the Inflation Reduction Act Policy issues related to vaccines

Client expense: $920,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

H.R. 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 2630: SAFE STEP ACT; ALL PROVISIONS H.R. 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS H.R. 5378: LOWER COSTS, MORE TRANSPARENCY ACT; ALL PROVISIONS H.R. 7383: RETAINING ACCESS AND RESTORING EXCLUSIVITY (RARE) ACT; ALL PROVISIONS H.R. 7623: TELEHEALTH MODERNIZATION ACT OF 2024; ALL PROVISIONS H.R. 7829: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2024; ALL PROVISIONS H.R. 8702: IMPROVING SENIORS' TIMELY ACCESS TO CARE ACT OF 2024; ALL PROVISIONS H.R. 9774: HEALTH CARE AFFORDABILITY ACT OF 2024; ALL PROVISIONS S. 652: SAFE STEP ACT; ALL PROVISIONS S. 1339: PHARMACY BENEFIT MANAGER REFORM ACT; ALL PROVISIONS S. 1375: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S. 2973: MODERNIZING AND ENSURING PBM ACCOUNTABILITY ACT; ALL PROVISIONS S. 3821: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2024; ALL PROVISIONS S. 4518: IMPROVING SENIORS' TIMELY ACCESS TO CARE ACT OF 2024; ALL PROVISIONS S. 5194: HEALTH CARE AFFORDABILITY ACT OF 2024; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING PHARMACY BENEFIT MANAGER PRACTICES GENERAL DISCUSSIONS REGARDING THIRD-PARTY ENTITIES THAT CONTRACT WITH EMPLOYER-SPONSORED HEALTH PLANS TO IMPORT PRESCRIPTION DRUGS FROM OUTSIDE THE UNITED STATES, ALSO KNOWN AS ALTERNATIVE FUNDING PLANS GENERAL DISCUSSIONS REGARDING THE 2025 FISCAL YEAR APPROPRIATIONS; PROVISIONS RELATING TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS, HEALTH AND HUMAN SERVICES AND RELATED AGENCIES, FOOD AND DRUG ADMINISTRATION AND RELATED AGENCIES, CENTER FOR DISEASE CONTROL AND PREVENTION AND RELATED AGENCIES, NATIONAL INSTITUTES OF HEALTH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION; AND POLICY RIDERS IN DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 1305: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2023; ALL PROVISIONS H.R. 2630: SAFE STEP ACT; ALL PROVISIONS H.R. 2940: THE PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UP SURGING RESISTANCE (PASTEUR) ACT OF 2023; ALL PROVISIONS H.R.: 3433: GIVE KIDS A CHANCE ACT OF 2024; ALL PROVISIONS H.R. 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS H.R. 5378: LOWER COSTS, MORE TRANSPARENCY ACT; ALL PROVISIONS H.R. 7383: RETAINING ACCESS AND RESTORING EXCLUSIVITY (RARE) ACT; ALL PROVISIONS H.R. 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; PROVISIONS REGARDING THE REAUTHORIZATION OF THE RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 7623: TELEHEALTH MODERNIZATION ACT OF 2024; ALL PROVISIONS H.R. 7829: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2024; ALL PROVISIONS H.R. 8702: IMPROVING SENIORS' TIMELY ACCESS TO CARE ACT OF 2024; ALL PROVISIONS H.R. 8964: MEDICAL RECORDS ACCESS FAIRNESS ACT OF 2024; ALL PROVISION H.R. 9774: HEALTH CARE AFFORDABILITY ACT OF 2024; ALL PROVISIONS S. 652: SAFE STEP ACT; ALL PROVISIONS S. 1339: PHARMACY BENEFIT MANAGER REFORM ACT; ALL PROVISIONS S. 1355: THE PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UP SURGING RESISTANCE (PASTEUR) ACT OF 2023; ALL PROVISIONS S. 1375: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S. 2973: MODERNIZING AND ENSURING PBM ACCOUNTABILITY ACT; ALL PROVISIONS S. 3821: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2024; ALL PROVISIONS S. 4426: PROMISING PATHWAY ACT 2.0; ALL PROVISIONS S. 4518: IMPROVING SENIORS' TIMELY ACCESS TO CARE ACT OF 2024; ALL PROVISIONS S. 4581: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2024; ALL PROVISIONS S. 5194: HEALTH CARE AFFORDABILITY ACT OF 2024; ALL PROVISIONS (DRAFT) CURES 2.0; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING PHARMACY BENEFIT MANAGER PRACTICES GENERAL DISCUSSIONS REGARDING PROPOSED FRAMEWORK FOR REFORMING NATIONAL INSTITUTES OF HEALTH GENERAL DISCUSSIONS REGARDING THE 2025 FISCAL YEAR APPROPRIATIONS; PROVISIONS RELATING TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS, HEALTH AND HUMAN SERVICES AND RELATED AGENCIES, FOOD AND DRUG ADMINISTRATION AND RELATED AGENCIES, CENTER FOR DISEASE CONTROL AND PREVENTION AND RELATED AGENCIES, NATIONAL INSTITUTES OF HEALTH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION; AND POLICY RIDERS IN DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL GENERAL DISCUSSIONS REGARDING THIRD-PARTY ENTITIES THAT CONTRACT WITH EMPLOYER-SPONSORED HEALTH PLANS TO IMPORT PRESCRIPTION DRUGS FROM OUTSIDE THE UNITED STATES, ALSO KNOWN AS ALTERNATIVE FUNDING PLANS

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5391/S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; Access and reimbursement of Part B Drugs in Medicare; Continued expansion of Telehealth services including in H.R. 3875/S. 3967, Expanded Telehealth Access Act and Telehealth Modernization Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act (PATIENT Act) of 2023; H.R. 4822, Health Care Price Transparency Act of 2023; Support for site neutrality policies in H.R. 5378, Lower Costs, More Transparency Act; Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022; Issues related to MACRA Reform including H.R. 2474, Strengthening Medicare for Patients and Providers Act; Support the passage of H.R. 5526/S. 3458, the Seniors' Access to Critical Medications Act; H.R. 6683, Preserving Seniors Access to Physicians Act of 2023; Issues related to prior authorization in H.R. 8702/S. 4518, Improving Seniors Timely Access to Care Act of 2024; S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment to CMS on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027."; H.R. 9096, the Pharmacists Fight Back Act; Long Term Care at Home Pharmacy Services in Medicare; Regulating fair and common-sense contracting guardrails between Part D plans/PBMs, and pharmacies; Comments to CMS on Proposed Rule Re: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments [CMS-1807-P]; H.R.4758, the Accelerating Kids Access to Care Act; H.R. 8107, the Ensuring Access to Medicaid Buy-in Programs Act of 2024; Comments to CMS on Draft Guidance Re: Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027; Request for Information to CMS on "Medicare $2 Drug list Model" (Executive Order 14087 of October 14, 2022); H.R.5074/S.5410, the Kidney PATIENT Act; H.R.4104/S.1976, the Preserving Patient Access to Home Infusion Act; H.R.10545, the American Relief Act, 2025;

Client expense: $412,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office

Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to COVID testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program. S. 1339 - Pharmacy Benefit Manager Reform Act of 2023 S. 1967 - Patients Before Middlemen Act of 2023 S. 2973 - Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act H.R. 2679 - Pharmacy Benefit Manager Accountability Act of 2023 H.R. 3285 - Fairness for Patient Medications Act H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023 H.R. 3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 H.R. 5378 - Lower Costs, More Transparency Act H.R. 2880 - Protecting Patients Against PBM Abuses Act

Client expense: $2,040,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues related to Medicare provider directories; Issues related to healthcare access, quality and costs; Issues related to healthcare transparency and consolidation; Issues related to Medicare Advantage; Issues related to site neutral payments; S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Ac; H.R. 5378, Lower Costs, More Transparency Act

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to pharmacy benefit management, including in H.R. 5378 (Lower Costs, More Transparency Act), S.2973 (Modernizing and Ensuring PBM Accountability Act), S.1339 (Pharmacy Benefit Manager Reform Act), and H.R.10545 (American Relief Act, 2025).

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Biosimilar Red Tape Elimination Act (S. 2305) Drug Patent Reform Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing, Rebates, Delinking Protecting Patients Against PBM Abuses Act (H.R. 2880) Drug Act (H.R. 6283) Robinson-Patman Act Reform Modernizing and Ensuring PBM Accountability (MEPA) Act (S.2973) Pharmacy Benefit Manager Transparency Act (S. 127) Pharmacy Benefit Manager Reform Act (S. 1339) Patients Before Middlemen Act (S.1967) Prescription Pricing for the People Act (S.113) Drug-Price Transparency for Consumers Act (S. 1250) Lower Cost, More Transparency Act (H.R. 5378) Continuing Resolution (H.R. 10545)

Client expense: $1,110,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE

Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691, Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R. 2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act; H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 3285, Fairness for Patient Medications Act; S. 2973 Modernizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0); H.R.3285 - Fairness for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 7535, Prescription Drug Supply Chain Pricing Transparency Act; S. 2305, Biosimilar Red Tape Elimination Act; H.R. 6986/S.3583, to address patent thickets; H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act; Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act); S.150, the Affordable Prescription Drug for Patients Act; S. 142, the Preserve Access to Affordable Generics and Biosimilars Act; S. 5503, H.R. 10362, the Patients Before Monopolies (PBM) Act; P.L. No: 118-158 and draft FY2025 Continuing Resolution, issues related to PBMs.

Client expense: $1,420,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, and VICP Program; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1355, PASTEUR Act of 2023; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 544: Veterans Infertility Treatment Act of 2023; all provisions of the bill H.R. 547: Better Care Better Jobs Act; all provisions of the bill H.R. 830: Help Ensure Lower Patient (HELP) Copays Act; all provisions of the bill H.R. 2534: Preserving Rules Ordered for The Entities Covered Through 340B Act of 2023(PROTECT 340B Act); all provisions of the bill H.R. 2880: Protecting Patients Against PBM Abuses Act; all provisions of the bill H.R. 5378: Lower Costs, More Transparency Act; all provisions of the bill H.R. 6283: Delinking Revenue from Unfair Gouging (DRUG) Act; all provisions of the bill S. 100: Better Care Better Jobs Act; all provisions of the bill S. 1339: Pharmacy Benefit Manager Reform Act; all provisions of the bill S. 1375: Help Ensure Lower Patient (HELP) Copays Act; all provisions of the bill S. 1542: Delinking Revenue from Unfair Gouging (DRUG) Act; all provisions of the bill S. 1967: Patients Before Middlemen (PBM) Act; all provisions of the bill S. 2973: Modernizing and Ensuring PBM Accountability Act; all provisions of the bill S. 3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; provisions related to drug costs P.L. 117-169: Inflation Reduction Act of 2022; implementation of Drug pricing provisions General discussions related to 340B Drug Pricing Program policy issues General discussions related to Pharmacy Benefit Manager policy issues General discussions related to Healthcare supply chain policy issues General discussions related to Drug cost and pricing policy issues General discussions related to caregiving support and awareness policy issues General discussions related to the Cancer Moonshot Initiative and the Advanced Research Projects Agency for Health (ARPA-H)

Client expense: $530,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA), White House Office

H.R. 830: Help Ensure Lower Patient (HELP) Copays Act; all provisions of the bill H.R. 5378: Lower Costs, More Transparency Act; all provisions of the bill H.R. 6283: Delinking Revenue from Unfair Gouging (DRUG) Act; all provisions of the bill S. 1339: Pharmacy Benefit Manager Reform Act; all provisions of the bill S. 1375: Help Ensure Lower Patient (HELP) Copays Act; all provisions of the bill S. 1542: Delinking Revenue from Unfair Gouging (DRUG) Act; all provisions of the bill S. 2973: Modernizing and Ensuring PBM Accountability Act; all provisions of the bill S. 3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; provisions related to drug costs General discussions related to Drug cost and pricing policy issues General discussions related to Healthcare supply chain policy issues

Client expense: $530,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

H.R. 2880: Protecting Patients Against PBM Abuses Act; all provisions of the bill H.R. 5378: Lower Costs, More Transparency Act; all provisions of the bill S. 1967: Patients Before Middlemen (PBM) Act; all provisions of the bill S. 2973: Modernizing and Ensuring PBM Accountability Act; all provisions of the bill S. 3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; provisions related to drug costs P.L. 117-169: Inflation Reduction Act of 2022; implementation of Parts B & D provisions General discussions related to Drug cost and pricing policy issues

Client expense: $530,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 456: Fairness in Orphan Drug Exclusivity Act H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1613: Drug Price Transparency in Medicaid Act of 2023 H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program H.R. 2679: Pharmacy Benefits Manager Accountability Act H.R. 2707: MADE in America Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3433: Give Kids a Chance Act of 2024 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3839: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act H.R. 4818: Treat and Reduce Obesity Act of 2023 H.R. 4895: Lowering Drug Costs for American Families Act - Provisions related to drug pricing H.R. 4988: Modern Authentication of Pharmaceuticals Act of 2023 H.R. 5376: Share the Savings with Seniors Act  H.R. 5378: Lower Costs, More Transparency Act H.R. 5391: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 5539: ORPHAN Cures Act H.R. 6283: Delinking Revenue from Unfair Gouging or DRUG Act H.R. 6664: Innovation in Pediatric Drugs Act of 2023 H.R. 7174: Ensuring Pathways to Innovative Cures (EPIC) Act: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7248: FDA Modernization Act 3.0 H.R. 7623: Telehealth Modernization Act of 2024 H.R. 7635: The 340B PATIENTS Act of 2024 H.R. 8574: 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act H.R. 9096: Pharmacists Fight Back Act S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1130: Health Care PRICE Transparency Act S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1497: Emergency Access to Insulin Act of 2023 S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 1589: Safeguarding Patients and Taxpayers Act S. 1967: PBM Act S. 2305: Biosimilar Red Tape Elimination Act S. 2333: Pandemic and All-Hazards Preparedness and Response Act S. 2474: Share the Savings with Seniors Act S. 2973: Modernizing and Ensuring PBM Accountability Act S. 3393: SUPPORT for Patients and Communities Reauthorization Act S. 3430: Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S. 5021: 340B PATIENTS Act of 2024 S. 5040: Protecting Patients from Deceptive Drugs Online Act S. 5459: Biosimilars Access and Affordability Act BioCompete Act (draft) Executive Order of February 28, 2024, Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) User fee policy issues Inflation Reduction Act of 2022 (P.L. 117-169) IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues Clinical trial diversity policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues

Client expense: $7,560,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitoring legislative and regulatory issues related to pharmacies. Prescription drug track and trace legislation, including implementation of related provisions in the Drug Quality and Security Act (P.L. 113-54) and PBM reform including S.2973 - Modernizing and Ensuring PBM Accountability Act and H.R.5378 - Lower Costs, More Transparency Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE